HEAL:LSE:LSE-iShares Healthcare Innovation UCITS ETF USD (Acc) (USD)

ETF | Others |

Last Closing

USD 7.8975

Change

-0.08 (-0.97)%

Market Cap

N/A

Volume

4.06K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-4.00 (-2.15%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+4.37 (+3.69%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.08 (+0.57%)

USD 572.76B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.11 (-0.59%)

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.45 (-0.64%)

USD 266.08B
0QZO:LSE 0QZO

-0.45 (-0.48%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.19 (-0.60%)

USD 208.06B
0QZ3:LSE Qualcomm Inc.

-1.12 (-0.67%)

USD 202.26B
0R24:LSE Intel Corp.

-0.67 (-2.92%)

USD 196.14B

ETFs Containing HEAL:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.74% 40% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.74% 37% F 46% F
Trailing 12 Months  
Capital Gain 20.02% 58% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.02% 56% F 60% D-
Trailing 5 Years  
Capital Gain 39.41% 58% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.41% 56% F 64% D
Average Annual (5 Year Horizon)  
Capital Gain 5.07% N/A N/A 56% F
Dividend Return 5.07% N/A N/A 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.08% N/A N/A 33% F
Risk Adjusted Return 18.06% N/A N/A 52% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike